Given the pivotal role of ROS equilibrium in oncogenesis, it is not unexpected that persistent activation of NRF2 is frequently observed in human malignancies as well as correlated with resistance to chemotherapy in well‐established neoplasms.17 Here, NFE2L2 is linked to neoplasm.